Menopur

Menotrophin, the active ingredient in Menopur, is a gonadotropin presented as a sterile injectable solution for subcutaneous use. It provides combined follicle‑stimulating hormone (FSH) and luteinizing hormone (LH) activity to treat infertility caused by anovulation and to support ovarian stimulation in assisted reproductive technology cycles.

GNH USA supplies Menopur as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, fertility clinics and pharmacies worldwide. The company adheres to stringent quality standards and provides reliable cold‑chain logistics for this biologic product globally.

Menopur, a gonadotropin, acts on the hypothalamic‑pituitary‑ovarian axis to promote follicular development.

Infertility due to anovulation: stimulates follicle growth to induce ovulation. Controlled ovarian stimulation for assisted reproductive technology (ART): supports development of multiple mature follicles for IVF cycles. Ovarian stimulation for intrauterine insemination (IUI): enhances egg maturation to improve pregnancy chances.

Menopur may be associated with a range of adverse reactions following subcutaneous administration.

Common Side Effects: - Injection site reactions: redness, swelling, or pain at the injection site. - Abdominal discomfort: mild cramping or bloating. - Mild ovarian hyperstimulation syndrome (OHSS): abdominal distension, nausea.

Serious or Rare Side Effects: - Severe ovarian hyperstimulation syndrome: rapid weight gain, shortness of breath, or fluid accumulation requiring hospitalization. - Thromboembolic events: deep vein thrombosis or pulmonary embolism. - Allergic reactions: urticaria, angioedema, or anaphylaxis.

Before initiating Menopur therapy, clinicians should consider several safety measures to minimize risks. - Monitor ovarian response: use serial ultrasound and estradiol measurements to adjust dose. - Avoid use in pregnancy: the drug is contraindicated during established pregnancy. - Screen for hormone‑sensitive cancers: assess patient history before treatment. - Adjust dose in polycystic ovary syndrome: start with lower dose to reduce OHSS risk. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Menopur can interact with other medications that affect hormonal balance or coagulation.

Major Interactions (Avoid): - GnRH antagonists: may diminish Menopur’s efficacy. - Oral contraceptives: suppress endogenous gonadotropins, reducing response. - High‑dose estrogen therapy: interferes with ovarian stimulation outcomes.

Moderate Interactions (Monitor Closely): - Thyroid hormone replacement: monitor thyroid function tests during treatment. - Anticoagulants: increased risk of thrombosis if severe OHSS develops.